NCT02841150View on ClinicalTrials.gov

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

PHASE1CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Healthy

Interventions

DRUG

IMBRUVICA (Treatment A)

IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.

DRUG

Ibrutinib (Treatment B)

Ibrutinib (test treatment), 1\*560 mg, tablet.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02841150 - Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules | Biotech Hunter | Biotech Hunter